Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 7/20 | 0.71 |
| ▸ | PI4KA | P42356 | 3/20 | 0.71 |
| ▸ | PI4K2B | Q8TCG2 | 3/20 | 0.71 |
| ▸ | PI4K2A | Q9BTU6 | 3/20 | 0.71 |
| ▸ | PI4KB | Q9UBF8 | 3/20 | 0.71 |
| ▸ | NSD2 | O96028 | 1/20 | 0.52 |
| ▸ | NSD3 | Q9BZ95 | 1/20 | 0.52 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.51 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.49 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.48 |
| ▸ | EGFR | P00533 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11015789 | 0.84 | ADORA2A (0.71) | ADORA2API4KAPI4K2BPI4K2API4KB | |
| SCHEMBL288237 | 0.84 | ADORA2A (0.71) | ADORA2API4KAPI4K2BPI4K2API4KB | |
| 9-Benzyl-9H-Adenine SCHEMBL104932 | 0.83 | ADORA2A (1.00) | ADORA2API4KAPI4K2BPI4K2API4KB | |
| SCHEMBL7744345 | 0.81 | PDE8A (0.57) | ADORA2API4KAPI4K2BPI4K2API4KB | |
| SCHEMBL11811272 | 0.77 | ADORA2A (0.64) | ADORA2API4KAPI4K2BPI4K2API4KB | |
| SCHEMBL22533530 | 0.76 | ADORA2A (0.71) | ADORA2API4KAPI4K2BPI4K2API4KB | |
| SCHEMBL21788552 | 0.76 | ADORA2A (0.76) | ADORA2API4KAPI4K2BPI4K2API4KB | |
| SCHEMBL11815862 | 0.76 | ADORA2A (0.66) | ADORA2API4KAPI4K2BPI4K2API4KB | |
| SCHEMBL22533851 | 0.75 | ADORA2A (0.74) | ADORA2API4KAPI4K2BPI4K2API4KB | |
| SCHEMBL6659204 | 0.75 | ADORA2A (0.74) | ADORA2API4KAPI4K2BPI4K2API4KB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1778239-A1 | ADENOSINE A3 RECEPTOR AGONISTS FOR THE TREATMENT OF DRY EYE DISORDERS INCLUDING SJOGREN'S SYNDROME | Can-Fite Biopharma Ltd. (IL) | 2007-05-02 | — | — | EP | claimed |
| US-7064112-B1 | Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist | CAN-FITE BIOPHARMA LTD. (IL) | 2006-06-20 | — | — | US | claimed |
| US-20060084626-A1 | Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist | CAN-FITE BIOPHARMA LTD. (IL) | 2006-04-20 | — | — | US | claimed |
| WO-2006011130-A1 | ADENOSINE A3 RECEPTOR AGONISTS FOR THE TREATMENT OF DRY EYE DISORDERS INCLUDING SJOGREN’S SYNDROME | CAN-FITE BIOPHARMA LTD. (IL) | 2006-02-02 | — | — | WO | claimed |
| US-5688774-A | ANTIINFLAMMATORY AGENTS, HYPOTENSIVE AGENTS AND CARDIOVASCULAR DISORDERS | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1997-11-18 | — | — | US | claimed |
| EP-3906034-A1 | AN A3 ADENOSINE RECEPTOR LIGAND FOR USE FOR ACHIEVING A FAT LOSS EFFECT | Can-Fite Biopharma Ltd. (IL) | 2021-11-10 | — | — | EP | disclosed |
| CN-113543790-A | Use of A for achieving a fat-reducing effect3Adenosine receptor ligands | 坎-菲特生物药物有限公司 | 2021-10-22 | — | — | CN | disclosed |
| CN-108367016-B | A3 adenosine receptor ligands for the treatment of ectopic fat accumulation | 坎-菲特生物药物有限公司 | 2021-07-16 | — | — | CN | disclosed |
| US-20200384009-A1 | A3 ADENOSINE RECEPTOR LIGAND FOR USE IN TREATING ECTOPIC FAT ACCUMULATION | CAN-FITE BIOPHARMA LTD. (IL) | 2020-12-10 | — | — | US | disclosed |
| EP-3380104-B1 | AN A3 ADENOSINE RECEPTOR LIGAND FOR USE IN TREATING ECTOPIC FAT ACCUMULATION | CAN FITE BIOPHARMA LTD (IL) | 2020-11-11 | — | — | EP | disclosed |
| US-10780106-B2 | Method for treating NASH accompanied by fibrosis using Cl-IB-MECA | CAN-FITE BIOPHARMA LTD. (IL) | 2020-09-22 | — | — | US | disclosed |
| CN-111447953-A | A3 adenosine receptor ligands for the management of cytokine release syndrome | 康菲生物制药有限公司 | 2020-07-24 | — | — | CN | disclosed |
| CN-101365430-A | Adenosine a3 receptor agonists for the treatment of dry eye disorders | CAN FITE BIOPHARMA LTD (IL) | 2009-02-11 | — | — | CN | disclosed |
| CN-101330909-A | Use of A3 adenosine receptor agonist in osteoarthritis treatment | CAN FITE BIOPHARMA LTD (IL) | 2008-12-24 | — | — | CN | disclosed |
| US-20080300213-A1 | Use of A3 Adenosine Receptor Agonist in Osteoarthritis Treatment | CAN-FITE BIOPHARMA LTD. (IL) | 2008-12-04 | — | — | US | disclosed |
| EP-1976494-A1 | ADENOSINE A3 RECEPTOR AGONISTS FOR THE TREATMENT OF DRY EYE DISORDERS | Can-Fite Biopharma Ltd. (IL) | 2008-10-08 | — | — | EP | disclosed |
| WO-2007086044-A1 | ADENOSINE A3 RECEPTOR AGONISTS FOR THE TREATMENT OF DRY EYE DISORDERS | CAN-FITE BIOPHARMA LTD. (IL) | 2007-08-02 | — | — | WO | disclosed |
| EP-1778239-A1 | ADENOSINE A3 RECEPTOR AGONISTS FOR THE TREATMENT OF DRY EYE DISORDERS INCLUDING SJOGREN'S SYNDROME | Can-Fite Biopharma Ltd. (IL) | 2007-05-02 | — | — | EP | disclosed |
| WO-2006011130-A1 | ADENOSINE A3 RECEPTOR AGONISTS FOR THE TREATMENT OF DRY EYE DISORDERS INCLUDING SJOGREN’S SYNDROME | CAN-FITE BIOPHARMA LTD. (IL) | 2006-02-02 | — | — | WO | disclosed |
| US-5688774-A | ANTIINFLAMMATORY AGENTS, HYPOTENSIVE AGENTS AND CARDIOVASCULAR DISORDERS | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1997-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200384009-A1 | A3 ADENOSINE RECEPTOR LIGAND FOR USE IN TREATING ECTOPIC FAT ACCUMULATION | GPR119, ADORA2A, FABP4 | ADORA2A 2/4885PI4KA 1590/4885PI4K2B 1287/4885 |
| US-10780106-B2 | Method for treating NASH accompanied by fibrosis using Cl-IB-MECA | GPR119, FABP1, INSR | ADORA2A 6/4885PI4KA 2215/4885PI4K2B 1409/4885 |
| US-20080300213-A1 | Use of A3 Adenosine Receptor Agonist in Osteoarthritis Treatment | ADORA3, ADORA2A, ADORA1 | ADORA2A 2/4885PI4KA 2289/4885PI4K2B 2970/4885 |
| US-20060084626-A1 | Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist | ADORA2A, ADORA3, ADORA1 | ADORA2A 1/4885PI4KA 2210/4885PI4K2B 2647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.